A 4-year retrospective claims analysis of oral corticosteroid use and health conditions in newly diagnosed Medicare FFS patients with COPD
We analyzed four years of administrative claims data for Medicare fee-for-service (FFS) beneficiaries to provide insights on systemic oral corticosteroid (OCS) use patterns, associated health conditions, and acute events among patients newly diagnosed with chronic obstructive pulmonary disease (COPD). This progressive inflammatory disease of the lungs is characterized by acute exacerbations that may lead to increased mortality. Short courses of systemic corticosteroids (SCS) are recommended to reduce recovery time from exacerbations, although SCS use has been associated with increased risk of adverse events. After an introduction, this paper is organized as follows:
- Materials and methods
- Results
- Discussion
- Conclusion
Explore more tags from this article
About the Author(s)
Dane Hansen
Michael Pollack
Alejandro P Comellas
Sanjay Sethi
Anthony Staresinic
John Styczynski
Norbert Feigler
A 4-year retrospective claims analysis of oral corticosteroid use and health conditions in newly diagnosed Medicare FFS patients with COPD
Using systemic oral corticosteroid (OCS) in treatment of chronic obstructive pulmonary disease (COPD) has risks, highlighting the need for prevention and therapy.